Clinical Trial: 20133

Trial Status: Closed
Disease Type: Lymphoma
Trial ID 20133
Sponsor ID MOR208C310

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-Intermediate and High-Risk Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Principal Investigator
Mitul Gandhi, MD
4 Locations


Fairfax Office

Gainesville Office

Alexandria Office

Loudoun Office

Learn More About This Trial
Other Relevant Trials
Trial ID 21552
Sponsor ID RGX-104-001

“A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (RGX-104-001)”

Trial ID 2204+J+A243:I272
Sponsor ID M23-362

A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)

Principal Investigator
Mitul Gandhi, MD